Richard A Alm
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia and one in Canada.
Abstracts this author is presenting:
